Upcoming FDA decision · April 23, 2027
Deucrictibant PDUFA date: FDA decision expected April 23, 2027
189 days to goPharvaris N.V. (PHVS) →
The FDA is expected to decide on Deucrictibant from Pharvaris N.V. in On-demand treatment of hereditary angioedema (HAE) attacks by the PDUFA target action date of April 23, 2027. For On-demand treatment of hereditary angioedema (HAE) attacks. NDA filing. Extracted from SEC filing: EX-99.1
A PDUFA date is the FDA's target deadline to complete its review of a drug application — approval, a complete response letter (CRL), or an extension are all possible. What is a PDUFA date? This page is research information, not financial advice.
Source: sec.gov · Data checked October 16, 2026. Confirm dates against the company's or the FDA's announcement before acting.
April 23
Target action date
Phase 3
Stage
Verified
Date confidence
—
FDA designations
Questions about this FDA decision
- When is the PDUFA date for Deucrictibant?
- The FDA's PDUFA target action date for Deucrictibant is April 23, 2027. The FDA can act before that date, and the review can be extended.
- What is Deucrictibant being reviewed for?
- The application under FDA review covers On-demand treatment of hereditary angioedema (HAE) attacks.
- Which company is developing Deucrictibant?
- Pharvaris N.V. (PHVS).
- What can happen on a PDUFA date?
- The FDA approves the application, issues a complete response letter (CRL) listing what must be fixed before approval, or extends the review (typically by three months after a major amendment).